Table 5 Subgroup analysis of the association between PNI and in-hospital mortality in patients with sepsis.

From: Prognostic nutritional indices predict 60 day mortality in ICU patients with sepsis

Variable

N (%)

PNI Levels

HR (95% CI)

P value

P for interaction

Age

    

0.449

> 65

781 (47.36)

Q1

Reference

  
  

Q2

0.64 (0.45–0.91)

0.013

 
  

Q3

0.46 (0.31–0.7)

< 0.001

 

≤ 65

868 (52.64)

Q1

Reference

  
  

Q2

0.7 (0.51–0.97)

0.033

 
  

Q3

0.33 (0.22–0.51)

< 0.001

 

Gender

    

0.341

F

656 (39.78)

Q1

Reference

  
  

Q2

0.6 (0.41–0.86)

0.006

 
  

Q3

0.46 (0.3–0.71)

0.001

 

M

993 (60.22)

Q1

Reference

  
  

Q2

0.72 (0.53–0.99)

0.041

 
  

Q3

0.35 (0.23–0.51)

< 0.001

 

Race

    

0.729

Black

167 (10.13)

Q1

Reference

  
  

Q2

0.67 (0.25–1.85)

0.444

 
  

Q3

0.49 (0.19–1.25)

0.135

 

Others

454 (27.53)

Q1

Reference

  
  

Q2

0.76 (0.52–1.1)

0.14

 
  

Q3

0.33 (0.19–0.58)

< 0.001

 

White

1028 (62.34)

Q1

Reference

  
  

Q2

0.6 (0.43–0.83)

0.002

 
  

Q3

0.42 (0.29–0.62)

< 0.001

 

Marital status

    

0.485

Divorced

120 (7.28)

Q1

Reference

  
  

Q2

0.41 (0.15–1.14)

0.087

 
  

Q3

0.08 (0.01–0.61)

0.015

 

Married

714 (43.30)

Q1

Reference

  
  

Q2

0.71 (0.48–1.05)

0.084

 
  

Q3

0.56 (0.37–0.84)

0.006

 

Others

222 (13.46)

Q1

Reference

  
  

Q2

0.73 (0.47–1.14)

0.171

 
  

Q3

0.44 (0.2–0.98)

0.043

 

Single

468 (28.38)

Q1

Reference

  
  

Q2

0.68 (0.41–1.12)

0.127

 
  

Q3

0.33 (0.17–0.62)

0.001

 

Widowed

125 (7.58)

Q1

Reference

  
  

Q2

0.44 (0.17–1.17)

0.101

 
  

Q3

0.38 (0.13–1.11)

0.076

 

Myocardial infarction

    

0.569

No

1409 (85.45)

Q1

Reference

  
  

Q2

0.71 (0.54–0.92)

0.01

 
  

Q3

0.41 (0.3–0.56)

< 0.001

 

Yes

240 (14.55)

Q1

Reference

  
  

Q2

0.52 (0.3–0.91)

0.022

 
  

Q3

0.33 (0.15–0.75)

0.008

 

CHF

    

0.519

No

1263 (76.59)

Q1

Reference

  
  

Q2

0.72 (0.55–0.95)

0.019

 
  

Q3

0.4 (0.28–0.55)

< 0.001

 

Yes

386 (23.41)

Q1

Reference

  
  

Q2

0.54 (0.34–0.86)

0.009

 
  

Q3

0.38 (0.2–0.7)

0.002

 

Diabetes

    

0.53

No

1317 (79.87)

Q1

Reference

  
  

Q2

0.64 (0.49–0.83)

0.001

 
  

Q3

0.41 (0.29–0.56)

< 0.001

 

Yes

332 (20.13)

Q1

Reference

  
  

Q2

0.79 (0.46–1.38)

0.416

 
  

Q3

0.32 (0.15–0.66)

0.002

 

Hypertension

    

0.418

No

794 (48.15)

Q1

Reference

  
  

Q2

0.64 (0.48–0.86)

0.003

 
  

Q3

0.34 (0.22–0.51)

< 0.001

 

Yes

855 (51.85)

Q1

Reference

  
  

Q2

0.75 (0.5–1.11)

0.153

 
  

Q3

0.5 (0.32–0.78)

0.002

 

Cerebrovascular disease

    

0.996

No

1473 (89.33)

Q1

Reference

  
  

Q2

0.67 (0.52–0.87)

0.003

 
  

Q3

0.39 (0.29–0.54)

< 0.001

 

Yes

176 (10.67)

Q1

Reference

  
  

Q2

0.63 (0.33–1.21)

0.168

 
  

Q3

0.35 (0.13–0.92)

0.033

 

Antibiotics

    

0.023

Beta-lactams

211 (12.80)

Q1

Reference

  
  

Q2

0.36 (0.19–0.68)

0.002

 
  

Q3

0.38 (0.18–0.78)

0.008

 

Glycopeptides

435 (26.38)

Q1

Reference

  
  

Q2

0.94 (0.6–1.47)

0.789

 
  

Q3

0.68 (0.41–1.13)

0.134

 

Macrolides

54 (3.27)

Q1

Reference

  
  

Q2

2.52 (0.55–11.55)

0.234

 
  

Q3

0.93 (0.15–5.63)

0.937

 

Others

949 (57.55)

Q1

Reference

  
  

Q2

0.63 (0.45–0.88)

0.006

 
  

Q3

0.28 (0.18–0.43)

< 0.001

 

Glucocorticoids

    

0.43

No

844 (51.18)

Q1

Reference

  
  

Q2

0.77 (0.54–1.09)

0.135

 
  

Q3

0.35 (0.21–0.56)

< 0.001

 

Yes

805 (48.82)

Q1

Reference

  
  

Q2

0.6 (0.43–0.82)

0.002

 
  

Q3

0.41 (0.28–0.59)

< 0.001

 
  1. Note: Results are expressed as HRs (95% CIs).
Back to article page